Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 17/20 | 1.00 |
| ▸ | RARB | P10826 | 17/20 | 1.00 |
| ▸ | RARG | P13631 | 16/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755036 | 1.00 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755033 | 1.00 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238257 | 0.91 | RARB (0.83) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238262 | 0.91 | RARB (0.83) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7624964 | 0.90 | RARB (0.82) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7628672 | 0.90 | RARA (0.81) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6754901 | 0.89 | RARA (0.80) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6754897 | 0.89 | RARA (0.80) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL30561848 | 0.89 | RARA (0.80) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8026108 | 0.89 | RARA (0.80) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084933-A | TLX fluorescent probe compound and preparation method and application thereof | 广州国家实验室 | 2024-05-28 | — | — | CN | claimed |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250376462-A1 | ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-11 | — | — | US | disclosed |
| WO-2025235403-A1 | DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025235400-A1 | NOVEL ISLET POTENCY ASSAY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-31 | — | — | US | disclosed |
| EP-4587557-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | Vertex Pharmaceuticals Incorporated (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120202293-A | Genetically engineered cells | 沃泰克斯药物股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4536807-A1 | A CELL SURFACE MARKER SIGNATURE FOR ARRHYTHMOGENIC PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES | Western Sydney Local Health District (AU) | 2025-04-16 | — | — | EP | disclosed |
| EP-4473088-A2 | CELL THERAPY FOR DIABETES | Vertex Pharmaceuticals Incorporated (US) | 2024-12-11 | — | — | EP | disclosed |
| WO-2024059776-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| CN-110551678-B | SC-beta cells, compositions and methods for producing the same | 哈佛学院校长同事会 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023235928-A1 | A CELL SURFACE MARKER SIGNATURE FOR ARRHYTHMOGENIC PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES | WESTERN SYDNEY LOCAL HEALTH DISTRICT (AU) | 2023-12-14 | — | — | WO | disclosed |
| CN-116981466-A | Stem cell differentiation and polymers | 沃泰克斯药物股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-4259779-A1 | METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES | Wisconsin Alumni Research Foundation (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023150493-A2 | CELL THERAPY FOR DIABETES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023044355-A1 | COMPOSITIONS AND METHODS FOR MITIGATING ALCOHOL LIVER DISEASE | CORNELL UNIVERSITY (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022125654-A1 | METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-106211757-B | Methods of treating metabolic syndrome-related conditions using retinoic acid receptor agonists | 康奈尔大学 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022112809-A1 | EFFICIENT AND RAPID SPECIFICATION OF SPINAL NEURONAL SUBTYPES FROM HUMAN PLURIPOTENT STEM CELLS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376462-A1 | ISLET CELL MANUFACTURING COMPOSITIONS AND METHODS OF USE | IAPP, PNLIP, CEL | RARA 3638/4885RARB 2557/4885RARG 2394/4885 |
| US-20260028591-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, CTNND1, CTNNBL1 | RARA 3678/4885RARB 3103/4885RARG 3332/4885 |
| US-20250243464-A1 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | IAPP, PNLIP, GPR119 | RARA 156/4885RARB 38/4885RARG 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.